Yourtyres.co.uk at REIFEN trade fair/automechanika: Improved usability and new shop features support business customers even more effectively
Yourtyres.co.uk, the online shop for business customers of Europe’s largest online tyre dealer Delticom, will present its partnership-based trading model for tyre dealers and automotive companies at REIFEN trade fair/automechanika in Frankfurt am Main. A particular focus at booth D 11 in hall 12.1 will be the newly integrated shop features that support dealers and workshops when providing advice to customers. Yourtyres.co.uk will also present the new website design, which enables work to be carried out even more efficiently thanks to the greater clarity, to the expert community for the first time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180806005435/en/
Yourtyres.co.uk will be exhibiting at REIFEN trade fair from 11-15 September 2018
New shop features: Support for advisory discussions
“In our recent improvements to the shop, we have focused on optimising usability. This enables us to save our customers not only money, but also time,” explains Andreas Faulstich, Head of Delticom B2B. “We will also once again be presenting our solutions for a future-proof tyre business and how the challenges of digitalisation can be used as an opportunity for your own growth. With Yourtyres.co.uk, dealers can benefit from the increasing trend for online business, yet still remain independent.”
One of the new shop features is the “virtual tyre advisor”, which was presented for the first time at this year's Tire Cologne and extends the type of sales views that can be displayed at Yourtyres.co.uk. “In this mode, the online shop displays the respective end consumer retail prices offered by the dealer instead of the dealer’s purchase prices,” explains Thorsten Orbach, head of dealer business at Delticom and Yourtyres.co.uk. “In order to use the feature, customers of the online shop need only to enter their individual surcharges beforehand – the personal end customer price is then calculated in real time using these surcharges and the purchase price.” This means that a separate dealer margin can be created for each product group. It is also possible to define the individual surcharge in percent as well as a minimum surcharge in pounds – or both.
The virtual tyre advisor also makes advisory discussions easier for both dealers and workshops. Based on just a few key questions, it will filter a number of suitable products from the comprehensive Yourtyres.co.uk range quickly and efficiently, presenting them in the form of a clear overview. “It takes into account preferences in driving behaviour, information on approximate annual mileage and the desired price and quality class,” explains Thorsten Orbach. “Together with the customer, the products can then be viewed, compared and selected individually – time-consuming manual searches are no longer necessary.”
Flexibility & new customers: The Yourtyres.co.uk trading model
While the shop features help to save time and provide more effective advice, the advantages of the trading model of Yourtyres.co.uk are aimed at making businesses future-proof as well as securing attractive margins and maximum flexibility for customers: the purchasing conditions of Yourtyres.co.uk thus mean that even small and medium-sized automotive companies with small storage capacities can offer the entire spectrum of the market at any time without having to commit themselves to minimum sales, purchase quantities or specific brands. In this way, they can still give independent advice and be their own boss. Thanks to high availability throughout the year, Delticom's own warehousing and international logistics expertise, even a special request can be fulfilled quickly and easily at any time.
Thanks to the proven service partner concept of Yourtyres.co.uk, B2B customers also have the opportunity to participate in the growing internet business and increasing online sales: with every tyre purchase in Delticom’s online shops such as Mytyres.co.uk, registered partners are recommended as service workshops to which the shipment can be delivered directly. This brings customers into the workshop and creates opportunities for follow-up business.
Yourtyres.co.uk is the exclusive online store from Delticom AG for workshops, retailers, wholesalers, tyre fitters/service stations and car accessories. With over 15 years’ expertise in the online tyre business, the Yourtyres.co.uk specialist B2B team offers its clients a spectacular range of car and motorbike tyres of all brands and dimensions for all types of vehicles, tyres for light trucks, trucks and buses, custom tyres, complete wheel sets, car spare parts and accessories, engine oil and batteries. In addition to favourable purchasing conditions, retail clients benefit from the online shop’s time-saving tyre search function, high availability, reliable delivery thanks to in-house warehouses, as well as a simple registration process with no hidden costs - from the very first tyre.
Information about the company: www.delti.com
Tyre tests: www.tyretest.com
insignis Agentur für
Kommunikation GmbH (GPRA)
Anne Lena Peters
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an